Clinical Trials Logo

Clinical Trial Summary

This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The primary objective is to evaluate the effect of sulindac on the presence or absence of progression of IPMN after up to 3 years of treatment. Patients without contraindications will be considered to be eligible and will be required to have a cross-sectional imaging study of the pancreas by CT scan or MRI within 3 months of study entry to document residual IPMNs and to rule out any evidence of pancreatic cancer. Patients will be randomized to receive either sulindac (200 mg p.o. BID) plus standard radiographic and endoscopic surveillance or placebo plus standard radiographic and endoscopic surveillance. Randomization will be stratified by (1) whether the patient had high-grade dysplasia identified in the initial resection specimen (resected patients only) and (2) whether the patient is taking metformin at the time of randomization.


Clinical Trial Description

This is a phase 2 multicenter, randomized, double-blind, placebo-controlled clinical trial of patients who have high-risk intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Patients will be randomized in a 1:1 fashion and stratified by whether the patient had high-grade dysplasia (yes vs. no vs. no resection) identified in the initial resection specimen (for resected subjects), and whether or not the patient is taking metformin at the time of randomization. Patients will be required to have undergone an MRI or CT angiogram for IPMN active surveillance in accordance with the standard practice at the enrolling institution within 3 months of study entry. The CT imaging study will be used to document baseline IPMN characteristics and to ensure that there is no evidence of a preexisting pancreatic cancer. Following randomization, patients will take the study drug or placebo twice daily for up to 3 years. Both the study drug arm and the placebo arm will undergo standard laboratory, radiographic, and endoscopic assessment for IPMN progression. Every 6 months, patients will undergo assessment of serum CMP, CBC, and CA19-9. EUS will be performed 6 months after randomization (+/- 4 weeks) and then annually. CT or MRI will be performed 1 year after randomization (+/- 4 weeks) and then annually. The intent of these timings is to have the EUS and CT/MRI be on an alternating 6-month schedule per standard of care. Patients, nurses, and physicians will be blinded to the randomization. Study drug will be provided to patients in the outpatient clinic or mailed to their home. Pill diaries will be provided at the time that the study drugs are given and will be evaluated every 6 months, at the time of routine follow-up. Safety and efficacy will be assessed throughout the treatment period. Assessment for study drug complications will be made by phone call every other month (in between routine follow-up) and at routine follow-up every 6 months by the attending surgeon or designee, until the end of the study. If a complication is identified, the study drug will be discontinued. Patient evaluations will be scheduled bi-annually for the primary endpoint and off-schedule evaluations may be made to address symptoms or clinical concerns as they arise. The investigators plan to accrue 100 patients and will follow all patients for up to 3 additional years until protocol defined progression or study closure, whichever occurs first. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04207944
Study type Interventional
Source Duke University
Contact Peter Allen, MD
Phone 919-684-6858
Email peter.allen@duke.edu
Status Recruiting
Phase Phase 2
Start date July 10, 2020
Completion date August 31, 2027

See also
  Status Clinical Trial Phase
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Not yet recruiting NCT03131076 - Quality of Life Assessment in Patients Who Are Under Surveillance for IPMN N/A
Recruiting NCT04993846 - Pancreatic Cancer and Oral Microbiome
Active, not recruiting NCT03305146 - Feasibility of Molecular Biology in Pancreatic Cyst Tumors N/A
Terminated NCT02044926 - Intraductal Papillary Mucinous Neoplasm With Malignant Change N/A
Completed NCT03914950 - TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer N/A
Completed NCT03578445 - Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions N/A
Recruiting NCT05117723 - Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer